In April 2017, the US Food and Drug Administration (FDA) approved midostaurin for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis associated with hematological neoplasm (SM-AHN) or mast cell leukemia (MCL), regardless of the KIT D816V mutation status. The gene discussed is KIT; the disease is systemic mastocytosis.